A state-of-the art HIV pill containing Dolutegravir, already widely used in rich countries, is set to become more quickly available at an affordable price in SA, thanks to an agreement announced by UNAIDS in New York on Thursday night. The deal guarantees a maximum price of $75 per person per year for three-in-one pills containing Dolutegravir, Tenofovir and Lamivudine, made by pharmaceutical companies Mylan and Aurobindo under licence from Viiv Healthcare. The development is important because it increases competition for SA’s next AIDS drug tender and is expected to help push down the cost of HIV treatment. It is also good news for patients, as recent research has shown Dolutegravir is more effective and better tolerated than antiretrovirals such as Efavirenz and Nevirapine. A working group established by the health department recently recommended switching patients to a once-daily fixed dose combination of Tenofovir, Lamivudine and Dolutegravir as first-line treatment, on both cli...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.